Sign in5 stories
Three new US patent applications cover LSD, ketamine and ibogaine paired with NeuroThera's PEA technology for conditions including depression, PTSD and substance use disorders.
SEC filing
A newly published U.S. patent application covers combining MDMA with N-acylethanolamines like PEA, as FDA's new psychedelics guidance also names MDMA as a covered drug class.
SEC filing
SciSparc invested C$2.7 million in the round, holding roughly 44.6% of NeuroThera afterward with its stake valued at about C$30 million.
SEC filing
The Phase IIb SCI-110 study now runs at three sites total: one in Connecticut, one in Germany, and one in Israel.
SEC filing
NeuroThera Labs added Hannover Medical School as a clinical trial site for its Phase IIb study of SCI-110 in adult Tourette Syndrome patients.
SEC filing